BR112015010126A2 - - Google Patents

Info

Publication number
BR112015010126A2
BR112015010126A2 BR112015010126A BR112015010126A BR112015010126A2 BR 112015010126 A2 BR112015010126 A2 BR 112015010126A2 BR 112015010126 A BR112015010126 A BR 112015010126A BR 112015010126 A BR112015010126 A BR 112015010126A BR 112015010126 A2 BR112015010126 A2 BR 112015010126A2
Authority
BR
Brazil
Application number
BR112015010126A
Other languages
Portuguese (pt)
Other versions
BR112015010126B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112015010126A2 publication Critical patent/BR112015010126A2/pt
Publication of BR112015010126B1 publication Critical patent/BR112015010126B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112015010126-7A 2012-11-06 2013-11-05 Uso de um anticorpo anti-alfa toxina (anti-at) de s. aureus isolado BR112015010126B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (2)

Publication Number Publication Date
BR112015010126A2 true BR112015010126A2 (US06174465-20010116-C00003.png) 2017-08-22
BR112015010126B1 BR112015010126B1 (pt) 2022-11-01

Family

ID=50685101

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015010126-7A BR112015010126B1 (pt) 2012-11-06 2013-11-05 Uso de um anticorpo anti-alfa toxina (anti-at) de s. aureus isolado

Country Status (14)

Country Link
US (3) US9845348B2 (US06174465-20010116-C00003.png)
EP (1) EP2928490B1 (US06174465-20010116-C00003.png)
JP (2) JP6506172B2 (US06174465-20010116-C00003.png)
KR (3) KR102272744B1 (US06174465-20010116-C00003.png)
CN (2) CN112316135A (US06174465-20010116-C00003.png)
AU (2) AU2013341421A1 (US06174465-20010116-C00003.png)
BR (1) BR112015010126B1 (US06174465-20010116-C00003.png)
CA (1) CA2890385C (US06174465-20010116-C00003.png)
ES (1) ES2912267T3 (US06174465-20010116-C00003.png)
HK (1) HK1215173A1 (US06174465-20010116-C00003.png)
MX (1) MX367082B (US06174465-20010116-C00003.png)
RU (1) RU2661406C2 (US06174465-20010116-C00003.png)
SG (2) SG11201503231YA (US06174465-20010116-C00003.png)
WO (1) WO2014074470A1 (US06174465-20010116-C00003.png)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 psl 결합 분자 및 그의 용도
KR102184343B1 (ko) 2011-11-07 2020-11-30 메디뮨 엘엘씨 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법
PL2917360T3 (pl) 2012-11-06 2020-06-29 Medimmune, Llc Przeciwciała dla determinant powierzchniowych S. aureus
KR102272744B1 (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
CA3115633A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574057A (en) * 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
CA2697538C (en) * 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
CA2768242C (en) * 2009-07-16 2015-11-17 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
EP2673373B3 (en) 2011-02-08 2021-06-02 MedImmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
PL2917360T3 (pl) 2012-11-06 2020-06-29 Medimmune, Llc Przeciwciała dla determinant powierzchniowych S. aureus
KR102272744B1 (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
CA2890385C (en) 2022-07-12
US10759849B2 (en) 2020-09-01
AU2018236849B2 (en) 2020-05-21
KR20150092738A (ko) 2015-08-13
US20190002540A1 (en) 2019-01-03
US20200109191A1 (en) 2020-04-09
JP2019142888A (ja) 2019-08-29
MX2015005481A (es) 2016-01-14
RU2661406C2 (ru) 2018-07-16
US10457724B2 (en) 2019-10-29
RU2015121617A (ru) 2016-12-27
HK1215173A1 (zh) 2016-08-19
JP6926138B2 (ja) 2021-08-25
US20160257733A1 (en) 2016-09-08
BR112015010126B1 (pt) 2022-11-01
AU2018236849A1 (en) 2018-10-18
SG11201503231YA (en) 2015-05-28
US9845348B2 (en) 2017-12-19
ES2912267T3 (es) 2022-05-25
MX367082B (es) 2019-08-05
EP2928490A4 (en) 2016-11-02
EP2928490A1 (en) 2015-10-14
CA2890385A1 (en) 2014-05-15
CN104780934A (zh) 2015-07-15
JP6506172B2 (ja) 2019-04-24
EP2928490B1 (en) 2022-03-30
AU2013341421A1 (en) 2015-06-04
JP2015536951A (ja) 2015-12-24
SG10201703677VA (en) 2017-06-29
WO2014074470A1 (en) 2014-05-15
KR20210083389A (ko) 2021-07-06
KR102272744B1 (ko) 2021-07-06
CN112316135A (zh) 2021-02-05
KR20200102533A (ko) 2020-08-31

Similar Documents

Publication Publication Date Title
BR112014017635A2 (US06174465-20010116-C00003.png)
BR112014017614A2 (US06174465-20010116-C00003.png)
BR112014017592A2 (US06174465-20010116-C00003.png)
BR112014017625A2 (US06174465-20010116-C00003.png)
BR112014017659A2 (US06174465-20010116-C00003.png)
BR112014017646A2 (US06174465-20010116-C00003.png)
AR092201A1 (US06174465-20010116-C00003.png)
BR112014017638A2 (US06174465-20010116-C00003.png)
BR112014017607A2 (US06174465-20010116-C00003.png)
BR112013027865A2 (US06174465-20010116-C00003.png)
BR112014017634A2 (US06174465-20010116-C00003.png)
BR112014017609A2 (US06174465-20010116-C00003.png)
BR112014017644A2 (US06174465-20010116-C00003.png)
BR112014017647A2 (US06174465-20010116-C00003.png)
BR112014017588A2 (US06174465-20010116-C00003.png)
BR112014017618A2 (US06174465-20010116-C00003.png)
BR112014013184A8 (US06174465-20010116-C00003.png)
BR112014017652A2 (US06174465-20010116-C00003.png)
BR112014017621A2 (US06174465-20010116-C00003.png)
BR112014017630A2 (US06174465-20010116-C00003.png)
BR112014017622A2 (US06174465-20010116-C00003.png)
BR112014017627A2 (US06174465-20010116-C00003.png)
BR112014017623A2 (US06174465-20010116-C00003.png)
BR112014017641A2 (US06174465-20010116-C00003.png)
BR112014017631A2 (US06174465-20010116-C00003.png)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/11/2013, OBSERVADAS AS CONDICOES LEGAIS